Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
| Autor: | Babak Eliassi-Rad, Manishi Desai, Natalie Sadlak, Gabrielle Fridman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Intraocular pressure netarsudil genetic structures rho kinase inhibitor Safety net Ocular hypertension Glaucoma Benzoates 03 medical and health sciences 0302 clinical medicine medicine Humans Pharmacology (medical) In patient Intraocular Pressure Aged Retrospective Studies Pharmacology business.industry Original Articles medicine.disease Ophthalmology Treatment Outcome 030104 developmental biology Emergency medicine beta-Alanine 030221 ophthalmology & optometry ocular hypertension Female business Safety-net Providers |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/jop.2020.0112 |
| Popis: | Purpose: To analyze the efficacy, safety, and accessibility of netarsudil 0.02% in patients with glaucoma (suspect, open or closed) at a safety-net academic medical center, Boston Medical Center (BMC). Methods: Retrospective chart review of patients prescribed netarsudil 0.02% for uncontrolled glaucoma at BMC between December 2017 and September 2019. Outcome measures included change in intraocular pressure (IOP) from baseline and evaluation of adverse events (AEs). Results: One hundred thirty patients (60% severe stage) were analyzed. The IOP reduction from baseline was about 3 mmHg. Fifty-four patients (42%) experienced an AE (eg, conjunctival hyperemia). Thirty-eight patients (29%) started netarsudil 0.02% in lieu of laser or surgery. Ninety-nine patients (71%) required prior authorization for insurance coverage of netarsudil 0.02%. Ten patients (7%) were unable to obtain netarsudil 0.02% due to issues with insurance coverage. Conclusion: Netarsudil 0.02% yielded significant IOP reduction in our cohort, however, to a smaller degree compared with prior studies that bore equivocal IOP reduction regardless of baseline IOP. Conjunctival hyperemia was the most common AE. In a limited number of patients, netarsudil 0.02% was not covered by insurance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|